The latter is a cancer vaccine consisting of autologous antigen-presenting cells, activated ex vivo and loaded with PAP (prostatic acid phosphatase) antigen, which is expressed by the majority of prostate cancer cells, and granulocyte-macrophage colony-stimulating factor (GM-CSF) to promote DC maturation [111]. Here, CSF2 is linked to prostate cancer.